ClinicalTrials.gg
RecruitingNCT07212907SUBTILEUpdated Nov 2, 2026

Probiotic and Ginger Supplement for Symptoms and Quality of Life in Functional Dyspepsia (SUBTILE)

An interventional study of Symbiosys® Stomalex (commercial name) in Functional Dyspepsia, sponsored by Biocodex. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Biocodex · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 2, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Functional dyspepsia (FD) is a frequent functional gastrointestinal disorder characterized by bothersome postprandial fullness, early satiety, epigastric pain, or burning, in the absence of any structural or metabolic cause. It significantly impairs quality of life and has limited therapeutic options, as conventional treatments such as proton pump inhibitors often show modest efficacy and may cause side effects with long-term use.

The gut and duodenal microbiota may play a role in FD. Spore-forming probiotics such as Bacillus coagulans MY01 and Bacillus subtilis MY02 have shown beneficial effects on FD symptoms in a randomized controlled trial. Ginger (Zingiber officinale) has a long history of traditional use as a gastroprotective agent and is supported by clinical and non-clinical data for improving gastric motility and related symptoms.

This study (SUBTILE, STO-253) is a prospective, interventional, multicenter trial conducted in France. It will evaluate the effect of a dietary supplement containing Bacillus coagulans MY01, Bacillus subtilis MY02, and ginger extract (50 mg, 20% gingerols) on FD symptoms and quality of life.

A total of 198 adult patients diagnosed with FD according to Rome IV criteria and with a normal upper endoscopy will be recruited in primary care and gastroenterology practices. Participants will take one capsule of the study product daily for 8 weeks.

The primary outcome is the change in the Patient Assessment of Gastrointestinal Symptom Severity (PAGI-SYM) total score between baseline and Week 8.

Secondary outcomes include changes in quality of life (PAGI-QoL), treatment adherence, use of concomitant medications, evolution of lower gastrointestinal symptoms, patient and physician global impressions of change (PGI-C, CGI-I), and satisfaction (Likert scales). An exploratory objective will assess psychological impact using the Hospital Anxiety and Depression Scale (HADS).

The study includes two site visits (baseline and end of study) and one telephone follow-up at Day 28. Safety and tolerability will be monitored through active reporting of adverse events.

The trial aims to provide new evidence on the role of probiotics combined with ginger extract as a non-pharmacological strategy to improve digestive comfort and quality of life in patients with functional dyspepsia.

Read the detailed description

Functional dyspepsia (FD) is one of the most common disorders of gut-brain interaction (DGBI), with an estimated prevalence of 7-8% in the general population. It is defined by Rome IV criteria as bothersome postprandial fullness, early satiety, epigastric pain, or burning, persisting for at least 3 months with onset at least 6 months before diagnosis, and without evidence of structural disease. FD is associated with impaired quality of life, psychological distress, and significant health care utilization. Current treatment options, including proton pump inhibitors and prokinetics, have limited efficacy and potential adverse effects when used long term.

Emerging evidence suggests a role of the gastrointestinal microbiota in FD pathophysiology. Alterations in duodenal microbiota, as well as small intestinal bacterial overgrowth (SIBO) promoted by chronic PPI use, have been reported. Probiotics may reduce dyspeptic symptoms, improve gut barrier function, modulate gastric motility, and exert anti-inflammatory effects.

A randomized controlled trial showed that Bacillus coagulans MY01 and Bacillus subtilis MY02 improved FD symptoms compared to placebo, with good safety and tolerability. In parallel, ginger (Zingiber officinale) has a well-documented gastroprotective effect, supported by both preclinical and clinical data, and has been shown to enhance gastric emptying and reduce upper gastrointestinal discomfort.

The present study (SUBTILE, STO-253) is a prospective, multicenter, interventional trial conducted in France, categorized as RIPH2 (research involving human participants at minimal risks and constraints) under French regulations. The study will evaluate the effect of a dietary supplement combining Bacillus coagulans MY01, Bacillus subtilis MY02, and ginger extract (50 mg, 20% gingerols), marketed in France since January 2025 as Symbiosys® Stomalex.

A total of 198 adult patients with FD (Rome IV criteria, normal endoscopy) will be recruited in primary care and gastroenterology practices. After providing informed consent, eligible participants will receive one capsule per day for 8 weeks. The study involves two in-person visits (baseline and Week 8) and one telephone follow-up at Day 28.

The primary endpoint is the change in total PAGI-SYM score from baseline to Week 8.

Secondary endpoints include changes in PAGI-QoL scores, treatment adherence, use of concomitant therapies, evolution of lower gastrointestinal symptoms, global impressions of change from both patients (PGI-C) and physicians (CGI-I), and satisfaction ratings. An exploratory endpoint evaluates psychological impact using the Hospital Anxiety and Depression Scale (HADS). Safety endpoints include frequency and severity of adverse events.

This study will provide additional clinical evidence on the potential role of spore-forming probiotics combined with ginger extract as a complementary non-pharmacological approach to improve digestive symptoms and quality of life in patients with functional dyspepsia.

02

Conditions studied

  • Functional Dyspepsia

Browse trials for

Keywords

  • Functional Dyspepsia
  • Bacillus coagulans MY01
  • Bacillus subtilis MY02
  • Ginger extract
  • Symbiosys Stomalex
  • Gut microbiota
  • Quality of life
  • Gastrointestinal symptoms
  • Spore-forming probiotics
  • Epigastric Pain Syndrome
03

In context

Dyspepsia

373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.

This study's planned enrollment of 198 is above the median of 88 across 303 interventional studies indexed under Dyspepsia.

Browse Dyspepsia studies →

Lead sponsor

Biocodex is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (male or female) aged ≥18 years.
  • Diagnosis of functional dyspepsia (FD) according to Rome IV criteria, with normal upper endoscopy including negative Helicobacter pylori test. Rome IV criteria define FD as the presence of one or more of the following symptoms: bothersome postprandial fullness, early satiety, epigastric pain, or epigastric burning, occurring at least 3 days per week during the last 3 months, with symptom onset at least 6 months prior to diagnosis.
  • PAGI-SYM total score >1 at baseline.
  • Ability to comply with study requirements and provide signed written before any study-related procedures.
  • Ability to complete the patient diary and questionnaires, in the investigator's opinion (sufficient reading and language comprehension).
  • For women of : Negative urine pregnancy test immediately before starting study product ; Agreement to use an approved method of for the duration of the study, unless meeting criteria for menopause (≥12 months of spontaneous amenorrhea). Women of childbearing potential are defined as all women physiologically capable of becoming pregnant, including those whose career, lifestyle, or sexual orientation normally precludes heterosexual intercourse.
  • Affiliation with a national health insurance or social security system.

Exclusion criteria

Exclusion Criteria:

  • Use within 2 weeks prior to baseline of treatments that could interfere with study evaluation, including Bacillus coagulans MY01, Bacillus subtilis MY02, ginger, peppermint, or antibiotics.
  • Known allergy or to any component of the product.
  • or specific warning related to the investigational product, including use of anticoagulants.
  • Use of therapy within the last 3 months.
  • Use of medications affecting gastrointestinal motility or sensitivity, including opioids, GLP-1 analogs, neuroleptics, antiemetics, or anticholinergics. (Stable antidepressant therapy allowed.)
  • Significant changes in diet or physical activity within 2 weeks prior to baseline or anticipated during the study period.
  • Active somatic or psychiatric disorder that could explain dyspeptic symptoms (e.g., active cancer, inflammatory disease). Stable use of one antidepressant is allowed for psychiatric indication.
  • Active Helicobacter pylori infection.
  • Predominant symptoms of gastroesophageal reflux disease (GERD) or irritable bowel syndrome (IBS).
  • Functional diarrhea or functional constipation as defined by Rome IV criteria.
  • History of abdominal surgery within the past year, except appendectomy, cholecystectomy, inguinal hernia repair, or splenectomy.
  • Pregnant or breastfeeding women.
  • Individuals under legal guardianship or curatorship.
  • Participation in another interventional clinical trial and receipt of an investigational product within 30 days prior to baseline.
  • Any acute or chronic medical or psychiatric condition that, in the investigator's judgment, could interfere with study assessments, including but not limited to severe hepatic or renal insufficiency, immunodeficiency, or substance abuse (alcohol or drugs).
  • Any personal condition or circumstance that, in the investigator's judgment, would make full participation in the study unlikely or impossible.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    Experimental: Probiotic and Ginger Supplement

    Patients with functional dyspepsia will receive one capsule per day of a dietary supplement containing Bacillus coagulans MY01, Bacillus subtilis MY02, and ginger extract (50 mg, 20% gingerols) for 8 weeks

    Dietary Supplement: Symbiosys® Stomalex (commercial name)

Interventions

  • Dietary supplementSymbiosys® Stomalex (commercial name)

    One oral capsule per day for 8 weeks. Each capsule contains Bacillus coagulans MY01, Bacillus subtilis MY02, and ginger root extract (50 mg, titrated to 20% gingerols).

06

What researchers measure

Primary outcomes

  1. Change in PAGI-SYM total score from baseline to Week 8

    The Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) is a validated questionnaire assessing severity of upper gastrointestinal symptoms. Total score ranges from 0 (none) to 5 (very severe). A decrease indicates symptom improvement.

    Time frame: Baseline (Day 0) and Week 8 (Day 56 ± 3 days)

Secondary outcomes

  1. Change in Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) Scores During Follow-up

    The PAGI-SYM (Patient Assessment of Upper Gastrointestinal Symptom Severity Index) is a validated patient-reported questionnaire assessing upper gastrointestinal symptoms. It includes 20 items scored on a 6-point Likert scale from 0 to 5 (0 = none, 5 = very severe). Subscale scores and the total score are calculated as the mean of completed items. Higher scores indicate worse symptom severity. A decrease from baseline reflects clinical improvement.

    Time frame: Baseline, Weeks 2, 4, 6, and 8

  2. Change in Patient Assessment of Upper Gastrointestinal Quality of Life (PAGI-QoL) Total Score

    The PAGI-QoL (Patient Assessment of Upper Gastrointestinal Quality of Life) is a validated patient-reported questionnaire measuring quality of life in functional dyspepsia. It includes 30 items, each scored on a 6-point Likert scale from 0 to 5. Subscale and total scores are calculated as the mean of completed items. Total score range: 0 (lowest quality of life) to 5 (highest quality of life). Higher scores reflect better quality of life.

    Time frame: Baseline, Week 4, and Week 8

  3. Patient adherence to study product assessed by patient diary

    Adherence will be assessed using a patient diary in which participants record daily intake of the study product. Adherence will be expressed as the proportion of days with documented capsule intake relative to the total number of days.

    Time frame: Week 4, and Week 8

  4. Use of concomitant medications for dyspeptic symptoms

    Proportion of patients using additional treatments for FD.

    Time frame: 2 months prior to inclusion and during study period (8 weeks)

  5. Evolution of lower gastrointestinal symptoms

    Change in presence/absence of symptoms compared to baseline.

    Time frame: Baseline and Week 8

  6. Patient's Global Impression of Change (PGI-C)

    The PGI-C (Patient's Global Impression of Change) is a self-reported 7-point Likert scale evaluating the patient's perception of change in health status since baseline. The scale ranges from 1 to 7, where 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Lower scores (1-3) indicate clinical improvement, 4 indicates stability, and higher scores (5-7) indicate worsening.

    Time frame: Week 8

  7. Clinical Global Impression of Improvement (CGI-I)

    The CGI-I (Clinical Global Impression of Improvement) is a physician-rated 7-point Likert scale assessing global improvement of the patient's condition compared with baseline. The scale ranges from 1 to 7, where 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Lower scores (1-3) indicate improvement, 4 indicates stability, and higher scores (5-7) indicate worsening.

    Time frame: Week 8

  8. Patient satisfaction with study product

    5-point Likert scale (1 = not at all satisfied; 5 = very satisfied).

    Time frame: Week 8

  9. Physician satisfaction with study product

    5-point Likert scale (1 = not at all satisfied; 5 = very satisfied).

    Time frame: Week 8

  10. Exploratory: Change in Hospital Anxiety and Depression Scale (HADS) score

    Evaluates impact on anxiety and depression. Total score ranges 0-21 per domain; higher scores indicate greater severity.

    Time frame: Baseline and Week 8

  11. Safety and tolerability (Adverse Events)

    Number, severity, and relationship of adverse events (AE) and serious adverse events (SAE).

    Time frame: From consent signature to Week 8 (end of study)

  12. Patient adherence to study product assessed by capsule count

    Adherence will be assessed by counting the number of remaining capsules at study visits. Adherence will be expressed as the proportion of capsules taken relative to the number of capsules dispensed.

    Time frame: Week 4 and Week 8

07

Study locations

2 of 2 sites recruiting
  • CHU Rouen
    Rouen, Boulevard Gambetta 76000, France
    Recruiting
    • Guillaume GOURCEROL, Pr · Contact
  • Gerard DASSA
    Istres, 13800, France
    Recruiting
    • Gerard DASSA, DR · Contact+33442550010
    • Gerard DASSA, PR · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.

Of 79 interventional studies with no phase under Dyspepsia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Oct 8, 2025
StartActual
Dec 22, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • CHU Rouen · Rouen, France
Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Gerard DASSA · Istres, FranceContact •••1141→•••0010Contact g•••@wanadoo.fr→none listed
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added
    Show site
    • CHU Rouen · Rouen, France
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Gerard DASSA · Istres, FranceContact •••1141→•••0010Contact g•••@wanadoo.fr→none listed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07212907
Lead sponsor
Biocodex
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Dec 22, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Pietro TODESSAYI
Contact
p.todessayi@biocodex.fr
+33 3 44 86 82 28
Sophie PARENT
Contact
s.parent-ext@biocodex.fr
Guillaume GOURCEROL, Pr
principal investigator · University Hospital, Rouen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion